Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database

被引：72

作者：

Garcia, M. ^{[1
]}

Aranburu, M. A. ^{[2
]}

Palacios-Zabalza, I. ^{[3
]}

Lertxundi, U. ^{[4
]}

Aguirre, C. ^{[1
,5
]}

机构：

[1] Galdakao Usansolo Hosp, Basque Country Pharmacovigilance Unit, Barrio Labeaga 46A, Galdakao 48960, Bizkaia, Spain

[2] Mutriku Primary Hlth Care, Mutriku, Spain

[3] Galdakao Usansolo Hosp, Serv Pharm, Galdakao, Spain

[4] Arabas Mental Hlth Network, Serv Pharm, Vitoria, Spain

[5] Univ Basque Country, Dept Pharmacol, Fac Med, Leioa, Spain

来源：

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS | 2016年 / 41卷 / 03期

关键词：

adverse drug reactions; bullous pemphigoid; gliptins;

D O I：

10.1111/jcpt.12397

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

What is known and objective: Bullous pemphigoid has been reported in association with gliptins. We describe a case, review the literature and analyse all cases of bullous pemphigoid recorded in the European pharmacovigilance database, EudraVigilance. Case summary: A 74-year-old woman, treated with vildagliptin/metformin for 12 months, developed bullous pemphigoid, confirmed by skin biopsy. The symptoms resolved within 7 months after vildagliptin/metformin withdrawal. What is new and conclusion: A search in EudraVigilance showed a disproportionality for bullous pemphigoid and gliptins, except alogliptin. These findings extend the evidence associating gliptins with this potentially serious disease.

引用

页码：368 / 370

页数：3

共 6 条

[1] Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature [J].

Attaway, Amy ;

Mersfelder, Tracey L. ;

Vaishnav, Sakshi ;

Baker, Joanne K. .

JOURNAL OF DERMATOLOGICAL CASE REPORTS, 2014, 8 (01) :24-28

[2] Bullous pemphigoid induced by vildagliptin: a report of three cases [J].

Bene, Johana ;

Jacobsoone, Aurelie ;

Coupe, Patrick ;

Auffret, Marine ;

Babai, Samy ;

Hillaire-Buys, Dominique ;

Jean-Pastor, Marie-Josephe ;

Vonarx, Marlene ;

Vermersch, Annie ;

Tronquoy, Anne-Fleur ;

Gautier, Sophie .

FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2015, 29 (01) :112-114

[3] Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology [J].

Feliciani, C. ;

Joly, P. ;

Jonkman, M. F. ;

Zambruno, G. ;

Zillikens, D. ;

Ioannides, D. ;

Kowalewski, C. ;

Jedlickova, H. ;

Karpati, S. ;

Marinovic, B. ;

Mimouni, D. ;

Uzun, S. ;

Yayli, S. ;

Hertl, M. ;

Borradori, L. .

BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (04) :867-877

[4] Bullous pemphigoid: Etiology, pathogenesis, and inducing factors: Facts and controversies [J].

Lo Schiavo, Ada ;

Ruocco, Eleonora ;

Brancaccio, Gabriella ;

Caccavale, Stefano ;

Ruocco, Vincenzo ;

Wolf, Ronni .

CLINICS IN DERMATOLOGY, 2013, 31 (04) :391-399

[5]

Pasmatzi Efi, 2011, Diabetes Care, V34, pe133, DOI 10.2337/dc11-0804

[6] Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin [J].

Skandalis, K. ;

Spirova, M. ;

Gaitanis, G. ;

Tsartsarakis, A. ;

Bassukas, I. D. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2012, 26 (02) :249-253

← 1 →